Biotech

All Articles

Cullinan, after $25M package, restore bispecific to Port

.Cullinan Therapy was wowed enough with Harbour BioMed's bispecific immune activator that it surrend...

A deeper check out Tough Biotech's Intense 15

.In this week's incident of "The Leading Pipe," we are actually diving right into Strong Biotech's a...

Lilly deals with period 2 failure of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's event commemorating the commendation ...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of substantial leadership hirings, firings a...

Lykos will definitely talk to FDA to reassess its decision complying with being rejected of MDMA treatment for post-traumatic stress disorder

.Observing a bad revealing for Lykos Therapies' MDMA candidate for trauma at a recent FDA advising b...

AN 2 halves roll call, quits period 3 test after data dissatisfy

.AN2 Therapeutics is actually reviewing its own service in feedback to uninspired midphase informati...

Merck pays $700M for bispecific, snooping autoimmune position and possibility to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying out $700 thousand ahead of time to challenge Amgen in a blood str...

Gilead spends J&ampJ $320M to leave licensing package for seladelpar

.Along With Gilead Sciences almost an FDA choice for its own liver health condition drug seladelpar,...

' All hands on deck' at Lilly as peers target being overweight market

.CEO David Ricks may see the business putting together tents at basecamp behind Eli Lilly in a try t...

Entero giving up personnel, leaving office as well as pausing R&ampD

.Bed mattress Liquidators has turned Entero Therapeutics white colored as a sheet. The financial ins...